C

Celldex Therapeutics

Develops antibody-based therapies targeting inflammatory diseases

Manager, Biologics Drug Substance External Manufacturing

Bioprocess & BiomanufacturingConfirmed live in the last 24 hours
Full-timeHampton, NJ, USA

About the Job

Requirements

  • A Bachelor's degree in Life Sciences, Pharmacy, Engineering, Chemistry, Microbiology, or a related discipline is required; an advanced degree is a plus.
  • At least 4 years of progressive experience in biotechnology, pharmaceutical, or biologics manufacturing environments.
  • At least 2 years of experience managing or working with biologics CDMOs.
  • At least 2 years of experience working with late-phase biologics programs.
  • Ability to travel 30% of the time.
  • Proficiency in Microsoft Outlook, Word, Excel, Project, PowerPoint, and Visio.
  • Interpersonal skills to effectively manage internal and external communications.

Responsibilities

  • Support GMP external manufacturing of clinical or commercial biologics drug substance.
  • Serve as a person-in-plant to monitor manufacturing batch operations, including upstream and downstream processing, at the CDMO site.
  • Review CDMO batch records, protocols, and reports; lead or support troubleshooting, process risk analysis, and manufacturing investigations.
  • Support process validation for commercialization of biologics drug substance.
  • Support the continuous process verification program for commercial biologics manufacturing.
  • Support technology transfer of pipeline drug candidates to external CDMOs.
  • Collaborate with internal and external cross-functional teams, including analytical, formulation, quality assurance, and regulatory teams, to support batch release, manufacturing investigations, testing, and stability programs.

Desired Qualifications

  • An advanced degree is a plus.

About the Company

Celldex Therapeutics

Develops antibody-based therapies targeting inflammatory diseases

Celldex Therapeutics develops antibody-based therapies for inflammatory, allergic, and autoimmune diseases, focusing on mast cell biology. Its lead program barzolvolimab is a humanized monoclonal antibody that inhibits KIT, reducing mast cell activity and inflammation; its pipeline includes other antibodies designed to engage the immune system or modulate disease pathways. The company leverages partnerships and licensing in addition to developing its own therapies to create a breadth of programs in its target areas. Its goal is to deliver therapies that lessen inflammation and autoimmune activity by targeting mast cells and related signaling pathways.

Company size
201-500
Company stage
IPO
Headquarters
Hampton, NJ
Founded
1983

Recently Posted Jobs

Explore more opportunities at Celldex Therapeutics

See more jobs